Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Five Dock, Australia Clinical Trials

A listing of Five Dock, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (35) clinical trials

A Gene Transfer Study for Hemophilia A

Hemophilia A is a condition in which blood is unable to clot effectively. It is caused by a mutation or deletion in the gene that is responsible for producing blood-clotting factor VIII protein. Individuals with hemophilia A suffer from repeated bleeding episodes, often into the joints, which can cause chronic ...

Phase

3.25 miles

Learn More »

Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ARO-HBV in healthy adult volunteers and participants with hepatitis B virus (HBV).

Phase

3.25 miles

Learn More »

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

This study will be conducted in two parts. Phase 1b is dose escalation in which patients are tested with SD-101 at various doses in combination with 200 mg pembrolizumab in patients with metastatic melanoma. Phase 2 will consist of 7 expansion cohorts to evaluate the efficacy and safety of SD-101 ...

Phase

4.21 miles

Learn More »

Assessing an Oral Janus Kinase Inhibitor AZD4205 in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer

A phase I/II, open-label, multicentre study to investigate the safety, tolerability, pharmacokinetics and anti-tumour activity of AZD4205 as monotherapy or in combination with Osimertinib in patients with EGFR mutant advanced stage non-small cell lung cancer (NSCLC). This study includes dose escalation part and dose expansion part.

Phase

4.32 miles

Learn More »

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced or have spread. Pharmacokinetics and pharmacodynamics of BMS-986205 when combined with Nivolumab and in combination with ...

Phase

4.64 miles

Learn More »

Study to Assess the Safety Pharmacokinetics and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke

This is a Phase 1b/2, double-blind (Principal Investigators and study subjects blinded, Sponsor unblinded), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DS-1040b in subjects with Acute Ischemic Stroke (AIS).

Phase

4.64 miles

Learn More »

Clinical Investigation of GT UrologIcal LLC's Artificial Urinary Sphincter (RELIEF II)

Prospective, non-randomized multi-center study testing the safety and efficacy of the GTU artificial urinary sphincter device in males with urinary incontinence. Up to 20 sites in Europe, Australia & New Zealand A sample size of 73 subjects is estimated to provide 80% power for efficacy. Accounting for 10% attrition, 82 ...

Phase

4.64 miles

Learn More »

Use of Hair to Diagnose the Presence of Breast Cancer

Using synchrotron X-ray diffraction, it has been reported that a hair from an individual with breast cancer exhibits a difference in its molecular structure compared to that of an individual without breast cancer. This difference is visible in the X-ray diffraction pattern as a ring superimposed on the pattern for ...

Phase

4.64 miles

Learn More »

A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema

A two part, multi-center study consisting of a Phase 1b open label, sequential dose escalation followed by a Phase 2a randomized, double-masked, dose expansion evaluating OPT-302 in combination with aflibercept in participants with persistent central-involved Diabetic Macular Edema.

Phase

4.64 miles

Learn More »

Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion Into Select Solid Tumors (Cervical)

This is a Phase 1/2, open-label, multi-arm study, of AGEN1884 in combination with AGEN2034 in subjects with advanced solid tumors including cervical cancer. AGEN2034 is a novel, fully human monoclonal immunoglobulin G4 (IgG4) antibody, designed to block program cell death-1 (PD-1). AGEN1884 is a novel, fully human monoclonal immunoglobulin G1 ...

Phase

4.64 miles

Learn More »